@misc{oai:repo.qst.go.jp:00083614,
 author = {Kuan, Hu and Lin, Xie and Zhang, Yiding and Masayuki, Hanyu and Honoka, Obata and Kotaro, Nagatsu and Hisashi, Suzuki and Zhang, Ming-Rong and Kuan, Hu and Lin, Xie and Zhang, Yiding and Masayuki, Hanyu and Honoka, Obata and Kotaro, Nagatsu and Hisashi, Suzuki and Zhang, Ming-Rong},
 month = {Sep},
 note = {CD133 has been recognized as a prominent biomarker for cancer stem cells (CSCs), which promote tumor relapse and metastasis. Herein, we developed a clinically relevant, stable, peptide-based positron emission tomography (PET) tracer, [64Cu]CM-2, for mapping CD133 protein in several kinds of cancers. Through the incorporation of a 6-aminohexanoic acid (Ahx) into the N-terminus of a CM peptide, we constructed a stable peptide tracer [64Cu]CM-2, which exhibited specific binding to CD133-positive CSCs in multiple preclinical tumor models. Both PET imaging and ex vivo biodistribution verified the superior performance of [64Cu]CM-2. Furthermore, the matched physical- and biological half-life of [64Cu]CM-2 makes it a state-of-art PET tracer for CD133. Therefore, [64Cu]CM-2 PET may not only enable the longitudinal tracking of CD133 dynamics in the cancer stem cell niche, but also provide a powerful and noninvasive imaging tool to track down CSCs in refractory cancers., 第4回日本核医学会分科会放射線薬品科学研究会 第20回放射性医薬品・画像診断薬研究会},
 title = {Development of a stable peptide-based PET tracer for detecting CD133-expressing cancer stem cells},
 year = {2021}
}